Cannabinoid receptor ligands and uses thereof

A compound of Formula (I)

• wherein
• X is carbon and Y is nitrogen or X is nitrogen and Y is carbon;
• R1 is hydrogen, (C1–C6)alkyl, halogen, or cyano;
• R2 and R3 are each independently (CH2)n-aryl or (CH2)n-heteroaryl, where n is 0, 1 or 2, and where said aryl and said heteroaryl moieties are optionally substituted with one or more substituents;
• L is —C(O)— or —C(R4)(OR5)—, where R4 is hydrogen or (C1–C6)alkyl and R5 is hydrogen, (C1–C6)alkyl, or taken together with R8 or R9 to form a morpholine or morpholin-3-one;
• R6 and R7 are each independently hydrogen or (C1–C6)alkyl, or R6 and R7 taken together form a partially or fully saturated carbocyclic ring;
• and
• R8 and R9 are each independently hydrogen, (C1–C6)alkyl, —C(O)(CH2)mR10, —SO2(CH2)nR10, or —(CH2)pR10, where m and n are 0, 1, or 2, p is 0, 1, 2 or 3, and R10 is selected from the group consisting of (C1–C8)alkyl, a partially or fully saturated cycloalkyl, aryl, heteroaryl, and a partially or fully saturated heterocycle, where said (C1–C8)alkyl, said cycloalkyl, said aryl, said heteroaryl and said heterocycle are optionally substituted with one or more substituents;
• a pharmaceutically acceptable salt thereof, a prodrug of said compound or said salt, or a solvate or hydrate of said compound, said salt or said prodrug.